Top

Published in:

Open Access 01-09-2019 | Neuroblastoma

Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma

Authors: Kleopatra Georgantzi, Apostolos V. Tsolakis, Åke Jakobson, Rolf Christofferson, Eva Tiensuu Janson, Lars Grimelius

Published in: Endocrine Pathology | Issue 3/2019

Abstract

Neuroblastoma (NB), the most common extracranial cancer in childhood, exhibits neuroendocrine (NE) differentiation. Two well-established NE markers, chromogranin A (CgA) and synaptophysin (syn), are used in the histopathological diagnostics. Our aims were to explore if the NE markers synaptic vesicle protein 2 (SV2) and vesicular monoamine transporter 1 (VMAT1) and 2 (VMAT2) also are expressed in human NB and if so, evaluate their usefulness in NB histopathological diagnostics. Tumor specimens from 21 NB patients, before and/or after chemotherapy, were immunostained for CgA, syn, SV2, VMAT1, and VMAT2. Clinical data was extracted from patients’ records. SV2 was highly expressed in NB, as was CgA while syn was less frequently expressed compared to the other two. Both VMATs were expressed in several NB, VMAT2 in more cases than VMAT1 and its expression was similar to syn. Chemotherapy did not affect the immunoreactivity in an obvious way. SV2 was highly expressed in NB and can thus be useful marker in NB diagnostics. VMAT1 and VMAT2 were also expressed in NB but similar to syn less reliable as tumor markers.

Machado JD, Diaz-Vera J, Dominguez N, Alvarez CM, Pardo MR, Borges R (2010) Chromogranins A and B as regulators of vesicle cargo and exocytosis. Cell Mol Neurobiol 30 (8):1181–1187. doi:https://doi.org/10.1007/s10571-010-9584-y CrossRefPubMed

Schafer MK, Weihe E, Eiden LE (2013) Localization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease. Adv Pharmacol 68:319–334. doi:https://doi.org/10.1016/B978-0-12-411512-5.00015-4 CrossRefPubMedPubMedCentral

Wimalasena K (2011) Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev 31 (4):483–519. doi:https://doi.org/10.1002/med.20187 CrossRefPubMed

Mendoza-Torreblanca JG, Vanoye-Carlo A, Phillips-Farfan BV, Carmona-Aparicio L, Gomez-Lira G (2013) Synaptic vesicle protein 2A: basic facts and role in synaptic function. Eur J Neurosci 38 (11):3529–3539. doi:https://doi.org/10.1111/ejn.12360 CrossRefPubMed

Valtorta F, Pennuto M, Bonanomi D, Benfenati F (2004) Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? Bioessays 26 (4):445–453. doi:https://doi.org/10.1002/bies.20012 CrossRefPubMed

O'Connor DT, Burton D, Deftos LJ (1983) Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab 57 (5):1084–1086. doi:https://doi.org/10.1210/jcem-57-5-1084 CrossRefPubMed

Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, Lloyd RV (2015) INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. Am J Clin Pathol 144 (4):579–591. doi:https://doi.org/10.1309/AJCPGZWXXBSNL4VD CrossRefPubMed

Wang H, Krishnan C, Charville GW (2019) INSM1 Expression in Peripheral Neuroblastic Tumors and Other Embryonal Neoplasms. Pediatr Dev Pathol 1093526619843725. doi:https://doi.org/10.1177/1093526619843725

Li YC, Kavalali ET (2017) Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets. Pharmacol Rev 69 (2):141–160. doi:https://doi.org/10.1124/pr.116.013342 CrossRefPubMedPubMedCentral

10.

Portela-Gomes GM, Lukinius A, Grimelius L (2000) Synaptic vesicle protein 2, A new neuroendocrine cell marker. Am J Pathol 157 (4):1299–1309. doi:https://doi.org/10.1016/S0002-9440(10)64645-7 CrossRefPubMedPubMedCentral

11.

Jakobsen AM, Ahlman H, Wangberg B, Kolby L, Bengtsson M, Nilsson O (2002) Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas. J Pathol 196 (1):44–50. doi:https://doi.org/10.1002/path.1002 CrossRefPubMed

12.

Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE (1986) Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A 83 (10):3500–3504CrossRefPubMedPubMedCentral

13.

Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A 93 (10):5166–5171CrossRefPubMedPubMedCentral

14.

Anlauf M, Eissele R, Schafer MK, Eiden LE, Arnold R, Pauser U, Kloppel G, Weihe E (2003) Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem 51 (8):1027–1040. doi:https://doi.org/10.1177/002215540305100806 CrossRefPubMed

15.

Tsolakis AV, Grimelius L, Stridsberg M, Falkmer SE, Waldum HL, Saras J, Janson ET (2009) Obestatin/ghrelin cells in normal mucosa and endocrine tumours of the stomach. Eur J Endocrinol 160 (6):941–949. doi:https://doi.org/10.1530/EJE-09-0001 CrossRefPubMed

16.

Molenaar WM, Baker DL, Pleasure D, Lee VM, Trojanowski JQ (1990) The neuroendocrine and neural profiles of neuroblastomas, ganglioneuroblastomas, and ganglioneuromas. Am J Pathol 136 (2):375–382PubMedPubMedCentral

17.

Georgantzi K, Skoldenberg EG, Stridsberg M, Kogner P, Jakobson A, Janson ET, Christofferson RHB (2018) Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors. Pediatr Hematol Oncol:1–10. doi:https://doi.org/10.1080/08880018.2018.1464087, 35CrossRef

18.

Carvalho Ade C, Parra ER, Zerbini MC, Alves VA, Capelozzi VL, Antonangelo L (2007) Morphometric evaluation of NB84, synaptophysin and AgNOR is useful for the histological diagnosis and prognosis in peripheral neuroblastic tumors (pNTs). Clinics (Sao Paulo) 62 (6):731–740CrossRef

19.

Hsiao RJ, Seeger RC, Yu AL, O'Connor DT (1990) Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest 85 (5):1555–1559. doi:https://doi.org/10.1172/JCI114604 CrossRefPubMedPubMedCentral

20.

Temple W, Mendelsohn L, Kim GE, Nekritz E, Gustafson WC, Lin L, Giacomini K, Naranjo A, Van Ryn C, Yanik GA, Kreissman SG, Hogarty M, Matthay KK, DuBois SG (2016) Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging 43 (3):474–481. doi:https://doi.org/10.1007/s00259-015-3179-2 CrossRefPubMed

Title: Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma
Authors: Kleopatra Georgantzi
Apostolos V. Tsolakis
Åke Jakobson
Rolf Christofferson
Eva Tiensuu Janson
Lars Grimelius
Publication date: 01-09-2019
Publisher: Springer US
Keywords: Neuroblastoma
Neuroblastoma
Cytostatic Therapy
Published in: Endocrine Pathology / Issue 3/2019
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI: https://doi.org/10.1007/s12022-019-09584-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Synaptic Vesicle Protein 2 and Vesicular Monoamine Transporter 1 and 2 Are Expressed in Neuroblastoma

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2019

A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology

Comprehensive Evaluation of Rare Pituitary Lesions: A Single Tertiary Care Pituitary Center Experience and Review of the Literature

TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up

The Utility of Intraoperative Cytological Smear and Frozen Section in the Surgical Management of Patients with Cushing’s Disease due to Pituitary Microadenomas

Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway

Systematic Review and Meta-analysis of the Impact of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP) on Cytological Diagnosis and Thyroid Cancer Prevalence

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page